Partner
Chartered Patent Attorney
European Patent Attorney
UPC Representative
UK Design Attorney
BSc Biochemistry, University College London
PhD Molecular and Developmental Biology, University of Cambridge
Thank you
Dev represents biotech and chemicals clients based in the UK, Europe, and US. He has worked in the life science and chemicals specialisms for over 25 years and has established a practice focusing on provision of strategic advice to early stage and rapid growth technology companies. Dev enjoys working with a wide variety of clients to help them develop valuable IP positions most often for companies seeking to partner or licence their technology.
He has advised companies and clients in diverse fields of biotherapeutics, gene editing, synthetic biology, speciality chemicals, medical devices, AI and computational biology. Dev's practice covers all areas of IP development and counselling including patents, designs, trade secrets and know how. His work involves the development of valuable patent positions in competitive global markets, as well as freedom-to-operate and patent landscape analysis. He advises on contentious issues and handles oppositions before the European Patent Office. In 2014 he successfully defended Freedom Innovations' Patent in an opposition referral to the EPO Enlarged Board of Appeal (G3/14).
Dev is a member of the Life Sciences Committee of the Chartered Institute of Patent Attorneys and regularly publishes and presents in the field of biotechnology intellectual property law. He is also authorised to act as a representative before the EU Unified Patents Court (UPC).
What people think about Devanand
Dev is pleased to work in a life sciences team awarded back-to-back Gold rating by the Financial Times Best European Patent Attorney Firms in 2023 and 2024.
The IAM Patent 1000 2024 edition says: "Crease is an expert when it comes to inventions relating to AI applications to various biological and medical innovations. He understands key issues of patentability and is able to craft successful patent applications as a result."
The IAM Patent 1000 2023 edition says: "With technical expertise, commercial savvy and an indelible enthusiasm for emerging technologies, Devanand Crease is an invaluable asset to his following in the biotech, sustainable technologies and medical device fields."
The IAM Patent 1000 2022 edition says: "in the words of one happy customer: You can count on Dev to have your best interests in mind when detailing your IP, with a strong understanding of where you are as a company, your financial resources and where you want to go commercially with your idea. This balance I have struggled to find elsewhere and for me is what sets Dev apart from other IP attorneys.”
The IAM Patent 1000 2020 edition states that Dev “has made an impression on peers with his “vast understanding of biochemistry and other life science fields”. With expertise in genomics, epigenetics and medical devices, he provides shrewd strategic guidance and support to companies across the United Kingdom, the United States and Asia”.
The IAM Patent 1000 2018 states that Dev's "doctorate in molecular biology and his technical training make him an ideal advocate for effectively and efficiently obtaining key European patents for biotech clients. He is knowledgeable, diligent, responsive to clients' needs and an excellent team player. He really is a patent strategist rather than simply a filer".
Dev has also been listed in Who's Who Legal every year since 2016 and is also recognised as a key lawyer in the Legal 500 2024 edition.
15.05.2023
Jonathan Goodacre promoted to PartnerKeltie is delighted to announce that Dr Jonathan Goodacre is a partner of the firm as of 1st May 2023.
24.08.2020
Working with start-ups – interview with Dev Crease.Dev Crease joined Keltie in 2004 just after he qualified as a UK and European patent attorney. Over past 16 years he has developed a thriving practice in the life sciences, chemical and medical technologies team based around advising rapid growth companies achieve value in their IP positions.
Thank you
